Meeting Banner
Abstract #2903

GluCEST imaging: a relevant biomarker of Huntington’s disease.

Jérémy Pépin1,2, Laetitia Francelle1,2, Maria-Angeles Carillo-de Sauvage1,2, Huu Phuc Nguyen3,4, Nicole El Massioui5,6, Valérie Doyère5,6, Emmanuel Brouillet1,2, and Julien Flament1,7

1CEA/DSV/I2BM/MIRCen, Fontenay-aux-Roses, France, 2CNRS Université Paris-Saclay UMR 9199, Fontenay-aux-Roses, France, 3Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany, 4Centre for Rare Diseases, University of Tuebingen, Tuebingen, Germany, 5Paris-Saclay Institute of Neuroscience, Université Paris-Sud, UMR 9197, Orsay, France, 6Centre National de la Recherche Scientifique, Orsay, France, 7INSERM UMS 27, Fontenay-aux-Roses, France

Huntington’s disease (HD) is an inherited neurodegenerative disease characterized by motor, cognitive and psychiatric symptoms. As glutamate has been shown to be a potential biomarker of neurodegenerative diseases, we used Chemical Exchange Saturation Transfer imaging of glutamate (gluCEST) to map cerebral glutamate distribution in mouse and rat models of HD. A decrease of [Glu] was measured in the striatum by MRS and gluCEST. In addition, good spatial resolution of gluCEST over MRS allowed identification of other afflicted brain regions such as corpus callosum. These results demonstrate the potential of gluCEST in providing relevant biomarkers of HD in the whole brain.

This abstract and the presentation materials are available to members only; a login is required.

Join Here